FDA Approves First Pill to Treat Moderate-to-Severe Crohn's
The FDA has approved the pill Rinvoq to treat moderate to severe Crohn's disease. (Source: WebMD Health)
Source: WebMD Health - May 19, 2023 Category: Consumer Health News Source Type: news
FDA Approves First Pill to Treat Moderate-to-Severe Crohn's Disease
FRIDAY, May 19, 2023 -- Patients with Crohn ’s disease have a new treatment option, following U.S. Food and Drug Administration approval of a pill called Rinvoq (upadacitinib).
Rinvoq is meant to treat adults with moderately to severely active... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 19, 2023 Category: General Medicine Source Type: news
FDA Approves First Pill to Treat Moderate-to-Severe Crohn's Disease, Rinvoq (upadacitinib)
FRIDAY, May 19, 2023 -- Patients with Crohn’s disease have a new treatment option, following U.S. Food and Drug Administration approval of a pill called Rinvoq (upadacitinib).
Rinvoq is meant to treat adults with moderately to severely active... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 19, 2023 Category: General Medicine Source Type: news
U.S. FDA Approves Rinvoq (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
NORTH CHICAGO, Ill., May 18, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib) for the treatment of adults with moderately to severely... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 19, 2023 Category: Drugs & Pharmacology Source Type: news
FDA Approves Upadacitinib (Rinvoq) for Crohn's Disease FDA Approves Upadacitinib (Rinvoq) for Crohn's Disease
The oral JAK inhibitor is for adults with moderately to severely active Crohn ' s disease whose condition failed to respond adequately or who can ' t tolerate one or more TNF inhibitors.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 18, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Alert Source Type: news
FDA approves first oral treatment for moderately to severely active Crohn ’s disease
FDA has approved Rinvoq (upadacitinib) for adults with moderately to severely active Crohn ’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Rinvoq is the first approved oral product available to treat moderately to severely active Crohn’s di (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 18, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
First JAK Inhibitor Approved for Crohn's Disease
(MedPage Today) -- The FDA approved upadacitinib (Rinvoq) for treating Crohn's disease, representing the first Janus kinase (JAK) inhibitor for the condition, the agency announced on Thursday.
Specifically, the once-daily pill is indicated for... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 18, 2023 Category: American Health Source Type: news
5-ASA Maintenance vs. No Maintenance in Newly Diagnosed Crohn's 5-ASA Maintenance vs. No Maintenance in Newly Diagnosed Crohn's
Despite guidelines against their use, 5-aminosalicylates are still widely used in Crohn ' s disease. How do disease outcomes compare in patients on 5-ASA monotherapy vs. no maintenance treatment?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Most Crohn's and Liver Disease Info on TikTok Is Accurate Most Crohn's and Liver Disease Info on TikTok Is Accurate
How does TikTok stack up on health information? Medical experts watched thousands of posts in two research projects to find out.WebMD Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2023 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Most Crohn ’s and Liver Disease Info on TikTok Is Accurate: Studies
In a new study, three medical residents reviewed 81 TikTok videos identified by a search for #crohnsdisease. All were posted since January 2021. They found of the 25% that were educational, 80% were accurate. (Source: WebMD Health)
Source: WebMD Health - May 16, 2023 Category: Consumer Health News Source Type: news
Effectiveness of Exclusive Enteral Nutrition in Crohn's Disease Effectiveness of Exclusive Enteral Nutrition in Crohn's Disease
This study aimed to elucidate the mechanisms of action in exclusive enteral nutrition in Crohn ' s disease. How does it promote anti-inflammatory and intestinal healing effects?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Amgen inks Crohn's disease collaboration worth a potential $530M
Health care giant Amgen is hiring a biotech to find new targets to treat inflammatory bowel diseases, to the tune of a potential $530 million. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 10, 2023 Category: Health Management Authors: Rowan Walrath Source Type: news
Small Increase in Lymphoma Risk Seen With Crohn Disease, Ulcerative Colitis
WEDNESDAY, May 10, 2023 -- Crohn disease (CD) and ulcerative colitis (UC) are associated with a slightly increased risk for lymphoma, according to a study published online April 13 in Clinical Gastroenterology and Hepatology.
Ola Olén M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 10, 2023 Category: Pharmaceuticals Source Type: news
First Phase 3 TREMFYA ® (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, May 9, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new efficacy and safety data from the Phase 3 QUASAR Induction Study evaluating the investigational use of TREMFYA® (guselkumab) in adults with moderately to severely active ulcerative colitis (UC)a who had an inadequate response or intolerance to conventionalb and/or advanced therapies.1,c The data show statistically significant and clinically meaningful improvements across symptomatic and histo-endoscopic outcome measures.1 Safety data were also consistent with the known safety profile of TREMFYA in ...
Source: Johnson and Johnson - May 9, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Win for Vedolizumab in Recurrent Crohn's Disease
(MedPage Today) -- CHICAGO -- Patients receiving vedolizumab (Entyvio) after undergoing bowel resection for advanced Crohn's disease in a randomized trial were significantly less likely to show endoscopic signs of recurrence compared with placebo... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - May 8, 2023 Category: Gastroenterology Source Type: news
